The GLP-1 saga epitomizes the unsustainable corruption within our medical system Story at a Glance: •In early 2023, a private conference with pharmaceutical industry leaders and investors highlighted anti-obesity and Alzheimer’s drugs as the next big money-makers and had the FDA head as its keynote speaker. •Since then, the FDA has taken questionable steps to promote these drugs, particularly Ozempic, an anti-obesity medication. There's been a massive push to get everyone, including children, on Ozempic, using shockingly aggressive marketing tactics. •This rush is eerily similar to the fen-phen craze, a temporary weight loss drug later pulled from the market for...